Since closing the funding round in November 2021, SpinaFX has achieved several additional key milestones, further positioning the Company to achieve its goal of bringing innovative, minimally invasive image-guided treatments to the global market:Built a world-class leadership team, including leading interventional neuroradiologist Dr. Kieran Murphy as Chief Medical OfficerAcquired existing device finished goods and manufacturing inventoryPartnered with StarFish Medical for commercialization contract manufacturing support"With these investments and acquisitions, SpinaFX now has the initial capital needed to commercialize Triojection® and the IP base to protect our competitive advantage for future expansion," said Igor Keselman, SpinaFX Executive Chair. SpinaFX is now well positioned to advance its products and accelerate regulatory approval in Canada, the EU, the U.S. and beyond. Headquartered in Ontario, Canada, SpinaFX is a medical device company bringing innovative, minimally invasive image-guided treatments to patients with back pain due to herniated discs.